ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "certolizumab pegol"

  • Abstract Number: 565 • 2014 ACR/ARHP Annual Meeting

    Effect of Certolizumab Pegol over 96 Weeks of Treatment on Inflammation of Spine and Sacroiliac Joints Measured By Magnetic Resonance Imaging in Patients with Axial Spondyloarthritis

    Jürgen Braun1, Walter P. Maksymowych2, Robert B. M. Landewé3, Christian Stach4, Owen Davies5, Tommi Nurminen4 and Desiree van der Heijde6, 1Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany, 2Department of Medicine, University of Alberta, Edmonton, AB, Canada, 3Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands, 4UCB Pharma, Monheim, Germany, 5UCB Pharma, Slough, United Kingdom, 6Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose Previous results from RAPID-axSpA (NCT01087762) demonstrated that certolizumab pegol (CZP) reduced inflammation in the sacroiliac joints (SIJ) and spine, as assessed by Magnetic Resonance…
  • Abstract Number: 2321 • 2013 ACR/ARHP Annual Meeting

    Long-Term Safety and Efficacy Of Certolizumab Pegol In Combination With Methotrexate In The Treatment Of Rheumatoid Arthritis: 5-Year Results From a 24-Week Randomized Controlled Trial and Open-Label Extension Study

    Josef S. Smolen1, Ronald van Vollenhoven2, Arthur Kavanaugh3, Vibeke Strand4, Jiri Vencovsky5, Michael H. Schiff6, Robert Landewé7, Boulos Haraoui8, Susan Walker9 and Désirée van der Heijde10, 1Medical University of Vienna and Hietzing Hospital, Vienna, Austria, 2Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, 3Division of Rheumatology Allergy and Immunology, University of California San Diego, San Diego, CA, 4Adjunct, Division of Immunology / Rheumatology, Stanford University, Palo Alto, CA, 5Institute of Rheumatology, Department of Clinical and Experimental Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, 6Rheumatology Division, University of Colorado, Denver, CO, 7Academic Medical Center Amsterdam & Atrium Medical Center, Heerlen, Netherlands, 8Centre Hospitalier de l’Université de Montréal, Montreal, QC, Canada, 9UCB Pharma, Raleigh, NC, 10Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: In the RAPID2 randomized controlled trial (RCT; NCT00160602), certolizumab pegol (CZP) +MTX every 2 weeks (Q2W) improved signs and symptoms of rheumatoid arthritis (RA)…
  • Abstract Number: 1520 • 2013 ACR/ARHP Annual Meeting

    Reduction Of Disease Burden On Workplace and Household Productivity In Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis, Over 48 Weeks Of Treatment With Certolizumab Pegol

    Désirée M. van der Heijde1, Jürgen Braun2, Martin Rudwaleit3, Oana Purcaru4 and Arthur Kavanaugh5, 1Dept of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Rheumazentrum Ruhrgebiet, Herne, Germany, 3Endokrinologikum, Berlin, Germany, 4UCB Pharma, Brussels, Belgium, 5Division of Rheumatology Allergy and Immunology, University of California San Diego, San Diego, CA

    Background/Purpose: Axial spondyloarthritis (axSpA) includes both ankylosing spondylitis (AS, meeting modified New York criteria) and axSpA with no sacroiliitis on X-ray (non-radiographic axSpA, nr-axSpA). AS…
  • Abstract Number: 1413 • 2013 ACR/ARHP Annual Meeting

    Long-Term Safety and Efficacy Of Certolizumab Pegol In Combination With Methotrexate In The Treatment Of Rheumatoid Arthritis: 5-Year Results From a 52-Week Randomized Controlled Trial and Open-Label Extension Study

    Edward Keystone1, Robert Landewé2, Ronald van Vollenhoven3, Bernard Combe4, Vibeke Strand5, Philip J. Mease6, Laura Shaughnessy7, Brenda VanLunen7 and Désirée van der Heijde8, 1University of Toronto, Toronto, ON, Canada, 2Academic Medical Center Amsterdam & Atrium Medical Center, Heerlen, Netherlands, 3Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, 4Montpellier University Hospital, Montpellier, France, 5Adjunct, Division of Immunology / Rheumatology, Stanford University, Palo Alto, CA, 6Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, 7UCB Pharma, Raleigh, NC, 8Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: In the RAPID1 randomized controlled trial (RCT; NCT00152386),1 certolizumab pegol (CZP) every 2 weeks (Q2W) plus MTX over 52 weeks (wks) provided rapid improvements…
  • Abstract Number: 431 • 2013 ACR/ARHP Annual Meeting

    Prediction Of Week 52 Treatment Response Based On A Week 12 Assessment In Rheumatoid Arthritis Patients Receiving Certolizumab Pegol: Comparison Of A Patient-Reported Instrument Versus Physician-Based Disease Activity Assessment

    Jeffrey R. Curtis1, Willem Koetse2, Jeymi Tambiah3, Lucian Ionescu4 and Yusuf Yazici5, 1Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 2UCB Pharma, Raleigh, NC, 3UCB Pharma, Smyrna, GA, 4UCB Pharma, Brussels, Belgium, 5New York University Hospital for Joint Diseases, New York, NY

    Background/Purpose: Guidelines support early intervention in rheumatoid arthritis (RA).1,2 The aim was to prospectively test whether outcome assessment at 12 weeks (wks) using a patient-reported…
  • Abstract Number: 433 • 2013 ACR/ARHP Annual Meeting

    Retrospective Analysis Of Certolizumab Pegol Use During Pregnancy: Update Of Impact On Birth Outcomes

    Megan E. B. Clowse1, Douglas C. Wolf2, Frauke Förger3, John J. Cush4, Christian Stach5, Gordana Kosutic6, Susan Williams6, Chidi Maduka6 and Uma Mahadevan7, 1Rheumatology, Duke University Medical Center, Durham, NC, 2Atlanta Gastroenterology Associates, Atlanta, GA, 3Department of Rheumatology and Clinical Immunology and Allergology, Inselspital, University of Bern, Bern, Switzerland, 4Baylor Research Institute and Baylor University Medical Center, Dallas, TX, 5UCB Pharma, Monheim, Germany, 6UCB Pharma, Raleigh, NC, 7UCSF Medical Center, San Francisco, CA

    Background/Purpose: Certolizumab pegol (CZP) is a PEGylated Fc-free anti-TNF approved in 45 countries for the treatment of rheumatoid arthritis (RA) and/or Crohn's disease (CD). An…
  • Abstract Number: 326 • 2013 ACR/ARHP Annual Meeting

    Reduction Of Disease Burden On Workplace and Household Productivity In Psoriatic Arthritis Over 48 Weeks Of Treatment With Certolizumab Pegol

    Arthur Kavanaugh1, Dafna D. Gladman2, Désirée M. van der Heijde3, Oana Purcaru4 and Philip J. Mease5, 1Division of Rheumatology Allergy and Immunology, University of California San Diego, San Diego, CA, 2Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 3Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 4UCB Pharma, Brussels, Belgium, 5Division of Rheumatology Research, Swedish Medical Center and University of Washington, Seattle, WA

    Background/Purpose: Compared to the general population, patients (pts) with psoriatic arthritis (PsA) suffer greater amounts of disability and substantially lower employment rates.1 To date there…
  • Abstract Number: 558 • 2012 ACR/ARHP Annual Meeting

    Rapid Improvements in Patient Reported Outcomes with Certolizumab Pegol in Patients with Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis: 24 Week Results of a Phase 3 Double Blind Randomized Placebo-Controlled Study

    Joachim Sieper1, Alan J. Kivitz2, A.M. Van Tubergen3, Atul A. Deodhar4, Geoffroy Coteur5, Franz Woltering6 and Robert B. M. Landewé7, 1Medical Department I, Rheumatology, Charité University Medicine, Berlin, Germany, 2Altoona Center for Clinical Research, Duncansville, PA, 3Department of Medicine, Maastricht University Medical Center, Maastricht, Netherlands, 4Oregon Health & Science University, Portland, OR, 5UCB Pharma, Brussels, Belgium, 6UCB Pharma, Monheim, Germany, 7Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands

    Background/Purpose: Axial spondyloarthritis (axSpA) is a form of spondyloarthritis (SpA) that includes both ankylosing spondylitis (AS) and non-radiographic axial SpA (nr-axSpA), as defined by the…
  • Abstract Number: 557 • 2012 ACR/ARHP Annual Meeting

    Effect of Certolizumab Pegol On the Multiple Facets of Psoriatic Arthritis As Reported by Patients: 24 Week Patient Reported Outcome Results of a Phase 3 Double Blind Randomized Placebo-Controlled Study

    Dafna D. Gladman1, Roy Fleischmann2, Geoffroy Coteur3, Franz Woltering4 and Philip J. Mease5, 1Centre for Prognosis Studies in The Rheumatic Diseases, Toronto Western Research Institute, University of Toronto, University Health Network, Toronto, ON, Canada, 2University of Texas Southwestern Medical Center at Dallas, Dallas, TX, 3UCB Pharma, Brussels, Belgium, 4UCB Pharma, Monheim, Germany, 5Seattle Rheumatology Associates, Seattle, WA

    Background/Purpose: RAPID-PsA (NCT01087788) reports efficacy and safety of certolizumab pegol (CZP), a PEGylated Fc-free anti-TNF, in psoriatic arthritis (PsA).1 The effect of different imputation methodologies…
  • Abstract Number: 1643 • 2012 ACR/ARHP Annual Meeting

    Outcomes of Pregnancy in Subjects Exposed to Certolizumab Pegol

    Megan E. B. Clowse1, Douglas C. Wolf2, Christian Stach3, Gordana Kosutic4, Susan Williams4, Ido Terpstra5 and Uma Mahadevan6, 1Rheumatology, Duke University Medical Center, Durham, NC, 2Atlanta Gastroenterology Associates, Atlanta, GA, 3UCB Pharma, Monheim, Germany, 4UCB Pharma, Raleigh, NC, 5UCB Pharma, Brussels, Belgium, 6University of California, San Francisco, San Francisco, CA

    Background/Purpose: Certolizumab pegol (CZP) is an Fc-free, PEGylated, anti-TNF approved in the US for the treatment of Crohn's disease (CD) and rheumatoid arthritis (RA). Pre-clinical…
  • Abstract Number: 1705 • 2012 ACR/ARHP Annual Meeting

    Effect of Certolizumab Pegol On Inflammation of Spine and Sacroiliac Joints in Patients with Axial Spondyloarthritis: 12 Week Magnetic Resonance Imaging  results of a Phase 3 Double Blind Randomized Placebo-Controlled Study

    Désirée van der Heijde1, Walter P. Maksymowych2, Robert B. M. Landewé3, Christian Stach4, Bengt Hoepken4, Andreas Fichtner4, Danuta Kielar5 and Jürgen Braun6, 1Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Department of Medicine, University of Alberta, Edmonton, AB, Canada, 3Academic Medical Center/University of Amsterdam & Atrium Medical Center, Amsterdam, Netherlands, 4UCB Pharma, Monheim am Rheim, Germany, 5UCB Pharma, Brussels, Belgium, 6Rheumazentrum Ruhrgebiet, Herne, Germany

    Background/Purpose: Axial spondyloarthritis (axSpA) includes both ankylosing spondylitis (AS) and non-radiographic axSpA (nr-axSpA) and is defined by the ASAS criteria.1 It is characterized by bone…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies